Product Images Donepezil Hydrochloride

This is a chart showing the change in ADAS-cog score from baseline, with mean values represented by symbols for Donepezil Hydrochloride Tablets 10mg/day, Donepezil Hydrochloride Tablets 5mg/day, and Placebo. The chart also shows clinical improvement and clinical decline from baseline, with weeks of drug treatment shown along the X-axis.*

This represents a graph displaying the cumulative percentage of patients with a change in ADAS-cog score while being treated with Donepezil Hydrochloride Tablets 5mg/day, Donepezil Hydrochloride Tablets 10mg/day, or a placebo. The x-axis represents the change from baseline score, while the y-axis shows the percentage of patients. The treatment group had a significantly higher percentage of patients experiencing cognitive improvement than the placebo group.*

This is a graph that shows the ADAS-cog (Alzheimer's Disease Assessment Scale - cognitive subscale) Change from Baseline over 12 weeks of drug treatment with different doses of Donepezil Hydrochloride (5mg/day and 10mg/day) and placebo. The y-axis shows the mean change score and the x-axis shows the weeks of treatment. The graph also shows clinical improvement and clinical decline, and it appears to have been a study testing the effectiveness of the different doses of Donepezil Hydrochloride in treating Alzheimer's disease.*

This is a chart showing the cumulative percentage of patients in different treatment groups with Alzheimer's disease and their change in ADAS-COG (a cognitive assessment) score from baseline. The treatment groups include 5mg/day and 10mg/day of Donepezil Hydrochloride tablets as well as a placebo group. The data shows that those in the 10mg/day group had the highest percentage of improved ADAS-COG scores, with 87% showing improvement after 24 weeks of treatment.*

This is a graph showing the percentage of patients who have experienced improvement or worsening changes in their CIBIC-plus rating while taking BN donepezil hydrochloride tablets, donepezil hydrochloride tablets or a placebo. The dosages mentioned are 10 mg/day and 5mg/day. The graph also shows four levels of improvement and worsening change in the patients' condition. There is not enough information to determine what the CIBIC-plus rating is or what it is used for.*

The text appears to be a graph showing the cumulative percentage of patients and their SIB (Severe Impairment Battery) change from baseline. The graph compares patients taking Donepezil Hydrochloride Tablets (10 mg/day) to those taking a placebo. There is a cumulative percentage of 100 at the top of the graph with SIB change from baseline on the Y-axis.*

This is a figure showing the Time Course of the Change from Baseline in ADCS-ADL-Severe Score for Patients Completing 6 Months of Treatment. It compares the clinical improvement and decline in patients who were administered with Donepezil Hydrochloride Tablets 10mg/day versus Placebo over a period of 6 months. The X-axis represents the months of drug treatment while the Y-axis represents the change from baseline in ADCS-ADL-Severe Score.*

This text is a graph that shows the cumulative percentage of patients for Donepezil Hydrochloride Tablets 10 mg/day and placebo. The x-axis shows the change from baseline in ADCS-ADL, while the y-axis represents the cumulative percentage of patients. There are no further details provided in the text.*

This is a medicine package for Donepezil HCI yellow 10mg tablets made by Torrent Pharmaceuticals Limited. The tablets are yellow and round in shape, and are stored at room temperature between 20-25°C (68°-77°F). The package includes 30 tablets and the product is compared to Aricept 10mg tablets. The expiration date is not provided, but the product has an NDC number of 7133505821 and a UPC code of 05219301523487.*